Anti-CD19/CD3 Antibody (Blinatumomab)
Catalog No.
F2117
Anti-CD19/CD3 Antibody (Blinatumomab)
Featured Products
Blinatumomab is a bispecific T cell engaging antibody (BiTE) developed by Amgen. It consists of two single-chain variable fragments (scFv), one targeting the CD19 antigen and the other targeting the CD3 antigen. Blinatumomab activates the killing effect of T cells on B cells by guiding T cells (CD3 positive) to B cells expressing CD19. The drug is mainly used to treat relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).
Dry ice
853426-35-4
-80°C
2 years
Liquid
1 mg/mL
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
Blincyto, Anatumomab
100 mM Pro 20 mM Arg pH 5.0.
Mouse
Unconjugated
Monoclonal
Protein A
(scFv-kappa-heavy)-(scFv-heavy-kappa)
ELISA, FACS, Kinetics, Functional assay, Animal Model
CD19/CD3
Please avoid freeze-thaw cycles.